The supplemental New Drug Application is supported by data from the Phase II TRANSCEND FL trial (NCT04245839), which showed ...

A Harvard Business School Healthcare Alumni Association Q&A with Stephanie J. Creary, Assistant Professor of Management at ...

One of the most significant drawbacks for a brand when partnering with individual medical journal platforms is the limitation ...

Despite missing the primary endpoint, SB-01 demonstrated durable clinical improvements and consistent results in the Phase ...

Sanofi secures exclusive rights to develop plozasiran in Greater China, enhancing treatment options for hypertriglyceridemia ...

Following the discontinuation of ALLO-647 due to a treatment-related death, Allogene will move forward with a streamlined ...

Medipost transitioned from cord blood banking to developing stem cell therapies, focusing on knee osteoarthritis and other ...

Computational chemistry combined with AI technologies has become a powerful tool for assessing small molecule properties, ...

Organizations commonly navigate outdated systems that make collaboration harder and breakthroughs slower, causing delays, ...

LENZ Therapeutics announced that FDA approved Presbyopia treatment Vizz making it the first and only aceclidine-based eye drop to be granted approval by the FDA, with samples estimated to reach the ...

Gene Mack, CEO, GAIN Therapeutics, shares how growing clinician confidence and strong early experiences helped accelerate ...

Aside from the MFN order, President Trump is also in the process of negotiating tariffs with countries all over the world. It ...